Abbott Laboratories (NYSE:ABT) Price Target Cut to $131.00 by Analysts at BTIG Research

Abbott Laboratories (NYSE:ABT) had its target price cut by BTIG Research from $140.00 to $131.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the healthcare product maker’s stock.

A number of other research analysts have also commented on the company. Daiwa Securities Group lowered their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Piper Sandler dropped their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Finally, Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $135.68.

Abbott Laboratories Stock Performance

ABT opened at $102.59 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $110.05 and its 200-day moving average is $121.57. The stock has a market cap of $178.68 billion, a PE ratio of 27.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.74. Abbott Laboratories has a twelve month low of $100.88 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.5%. Abbott Laboratories’s payout ratio is 67.74%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On Abbott Laboratories

Large investors have recently modified their holdings of the stock. Carr Financial Group Corp increased its stake in Abbott Laboratories by 2.0% in the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares in the last quarter. Gemmer Asset Management LLC lifted its stake in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after buying an additional 78 shares in the last quarter. Global Financial Private Client LLC boosted its holdings in shares of Abbott Laboratories by 3.3% in the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares during the period. Citizens & Northern Corp boosted its holdings in shares of Abbott Laboratories by 0.4% in the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after buying an additional 79 shares during the period. Finally, American National Bank of Texas increased its position in shares of Abbott Laboratories by 2.4% in the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after acquiring an additional 79 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Precision Oncology tests are now integrated into Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers and ~4,700 providers the ability to order and receive Abbott test results inside their clinical workflow — a direct adoption catalyst for tests such as Oncotype DX, OncoExTra and Oncodetect that can lift diagnostics volume and recurring revenue. Abbott expands access to Precision Oncology
• Positive Sentiment: Abbott is a strategic investor in Whoop’s $575M Series G round (company valued at ~$10.1B). That stake gives Abbott optionality in wearable/consumer biometric data and potential commercial partnerships as Whoop scales globally and eyes an IPO — a complementary play to Abbott’s diabetes and consumer health franchises. Whoop raises $575M, adds Abbott as strategic investor
• Positive Sentiment: Industry research flags the global medical nutrition market growing to ~$31.1B by 2035, with Abbott named among key innovators — a favorable long-term demand backdrop for Abbott’s Nutrition segment once it stabilizes. Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035
• Neutral Sentiment: Analyst note: BTIG trimmed its price target from $140 to $131 but maintained a Buy rating — a modest near-term view change but still a constructive stance implying upside from current levels. BTIG lowers ABT price target
• Neutral Sentiment: Recent analyst and media coverage highlights a mixed fundamental picture: Nutrition sales have pressured near-term growth, but Medical Devices (including FreeStyle Libre CGM and structural heart/electrophysiology businesses) remain strong; management is executing turnaround plans and pursuing the Exact Sciences acquisition — important long-term catalysts but with near-term execution risk. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Negative Sentiment: Price action & volatility: recent trading showed a pullback to near 52‑week lows amid sector rotation and nutrition weakness, which has pressured sentiment even though core businesses remain solid. Short-term selling and investor rotation remain risks. Abbott (ABT) Dips More Than Broader Market

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.